Modality
Vaccine
MOA
PD-L1i
Target
IL-17A
Pathway
Ferroptosis
NB
Development Pipeline
Preclinical
~Jul 2011
→ ~Oct 2012
Phase 1
~Jan 2013
→ ~Apr 2014
Phase 2
~Jul 2014
→ ~Oct 2015
Phase 3
~Jan 2016
→ ~Apr 2017
NDA/BLA
Jul 2017
→ Apr 2029
NDA/BLACurrent
NCT03249852
1,474 pts·NB
2020-06→2029-04·Recruiting
NCT08181268
2,116 pts·NB
2017-07→2027-02·Recruiting
3,590 total pts1 indication
Approved
CompletedCurrentUpcoming
Catalysts (2)
2027-02-2711mo awayPh3 Readout· NB
2029-04-283.1y awayPh3 Readout· NB
Trial Timeline
Q3Q42018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3
NDA/BLA
Recruit…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2027-02-27 · 11mo away
NB
Ph3 Readout
2029-04-28 · 3.1y away
NB
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT03249852 | NDA/BLA | NB | Recruiting | 1474 | PASI75 |
| NCT08181268 | NDA/BLA | NB | Recruiting | 2116 | ACR20 |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-1085 | Pfizer | Preclinical | FXIa | |
| Rilulemzoparlimab | Novartis | Phase 2/3 | KRASG12D | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| SNY-9600 | Sanofi | NDA/BLA | B7-H3 | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Nirafutibatinib | Bayer | Phase 2 | WRN | |
| Motainavolisib | Amgen | NDA/BLA | CD47 | |
| GIL-9779 | Gilead Sciences | Phase 1 | IL-17A | |
| BNT-8090 | BioNTech | Phase 2 | AuroraA | |
| Miriglumide | Alnylam | Phase 3 | CD3 |